Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.46 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20843168 | 0.90 | KDM1A (0.62) | KDM1ASMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL3230414 | 0.82 | KDM1A (0.57) | KDM1ASMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL11360234 | 0.81 | KDM1A (0.59) | KDM1ASMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL2449434 | 0.80 | KDM1A (0.58) | KDM1ASMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL23460614 | 0.78 | KDM1A (0.48) | KDM1ASMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL23460616 | 0.78 | KDM1A (0.48) | KDM1ASMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL31382449 | 0.78 | SMN1; SMN2 (0.56) | KDM1ASMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL31382451 | 0.78 | SMN1; SMN2 (0.56) | KDM1ASMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL2621377 | 0.78 | MEN1 (0.59) | KDM1ASMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL4830010 | 0.78 | MEN1 (0.59) | KDM1ASMN1; SMN2NPC1RAB9ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575167-B2 | Spiro compounds having stearoyl-CoA desaturase action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-05 | — | — | US | disclosed |
| US-20100069351-A1 | SPIRO COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069351-A1 | SPIRO COMPOUND AND USE THEREOF | SCD, SPR, SCD5 | KDM1A 1046/4885SMN1; SMN2 894/4885NPC1 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.